|NYSE: ZTS||Healthcare / Drug Manufacturers / USA|
|164.00||-2.24||-1.35%||Vol 775.83K||1Y Perf -15.56%|
|Mar 22nd, 2023 14:24 DELAYED|
|-0.79 -0.48%||- -|
|Target Price||207.88||Analyst Rating||Strong Buy 1.21|
|Potential %||26.50||Finscreener Ranking||★★+ 47.10|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 47.82|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 62.47|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★ 44.13|
|Price Range Ratio 52W %||51.64||Earnings Rating||Sell|
|Market Cap||76.00B||Earnings Date||4th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||1.31|
|EPS Growth Next 5 Years %||10.80|
|Avg. Weekly Volume||2.31M|
|Avg. Monthly Volume||1.95M|
|Avg. Quarterly Volume||2.08M|
Zoetis Inc. Class A (NYSE: ZTS) stock closed at 166.24 per share at the end of the most recent trading day (a 0.25% change compared to the prior day closing price) with a volume of 2.33M shares and market capitalization of 76.00B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.
The one-year performance of Zoetis Inc. Class A stock is -15.56%, while year-to-date (YTD) performance is 13.44%. ZTS stock has a five-year performance of 102.58%. Its 52-week range is between 124.1483 and 201.32, which gives ZTS stock a 52-week price range ratio of 51.64%
Zoetis Inc. Class A currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 14.76, a price-to-sale (PS) ratio of 11.35, a price to cashflow ratio of 37.70, a PEG ratio of 2.32, a ROA of 16.35%, a ROC of 18.35% and a ROE of 47.92%. The company’s profit margin is 27.33%, its EBITDA margin is 40.50%, and its revenue ttm is $6.04 Billion , which makes it $12.96 revenue per share.
Of the last four earnings reports from Zoetis Inc. Class A, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.31 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.21), with a target price of $207.88, which is +26.50% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Zoetis Inc. Class A has a dividend yield of 1.02% with a dividend per share of $1.50 and a payout ratio of 22.00%.
Zoetis Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.97, ATR14 : 4.00, CCI20 : -10.67, Chaikin Money Flow : 0.10, MACD : -0.02, Money Flow Index : 67.12, ROC : -2.53, RSI : 50.96, STOCH (14,3) : 52.70, STOCH RSI : 1.00, UO : 57.52, Williams %R : -47.30), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Gregory Norden (Option Excercise at a value of $0), Heidi C. Chen (Option Excercise at a value of $0), Jamie Brannan (Option Excercise at a value of $0), Kristin C. Peck (Option Excercise at a value of $363 206), Kristin C. Peck (Sold 10 000 shares of value $1 800 000 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Rimma Driscoll (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $150 605), Robert J. Polzer (Sold 1 120 shares of value $192 383 ), Roxanne Lagano (Option Excercise at a value of $1 730 996), Roxanne Lagano (Sold 21 678 shares of value $3 813 630 ), Wafaa Mamilli (Option Excercise at a value of $0), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 855 shares of value $301 085 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
CEO: Kristin C. Peck
Telephone: +1 973 822-7000
Address: 10 Sylvan Way, Parsippany 07054, NJ, US
Number of employees: 11 300
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.